Status:
COMPLETED
Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)
Lead Sponsor:
Axsome Therapeutics, Inc.
Conditions:
Migraine
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
MOVEMENT (Multimechanistic Treatment over Time of Migraine Symptoms) is a Phase 3 study to evaluate the long-term safety of chronic intermittent use of AXS-07 and to assess the effect of AXS-07 on mig...
Detailed Description
This study is a Phase 3, multicenter, open-label, trial to evaluate the long-term safety and efficacy of intermittent chronic dosing with AXS-07 in subjects with migraine attacks. Eligible subjects wi...
Eligibility Criteria
Inclusion
- Has participated in a prior study with AXS-07 for the treatment of migraine
Exclusion
- Has previously received any investigational drug or device or investigational therapy within 30 days before Screening, other than AXS-07
- Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
Key Trial Info
Start Date :
July 6 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 22 2020
Estimated Enrollment :
706 Patients enrolled
Trial Details
Trial ID
NCT04068051
Start Date
July 6 2019
End Date
September 22 2020
Last Update
October 10 2023
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Site
Birmingham, Alabama, United States, 32516
2
Clinical Research Site
Birmingham, Alabama, United States, 32542
3
Clinical Research Site
Mobile, Alabama, United States, 36608
4
Clinical Research Site
Phoenix, Arizona, United States, 85004